post-title portfolio-title Aspirin Tablets 75mg Enteric Coated Taj Pharma 2020-01-02 12:40:37 no no

Aspirin Tablets 75mg Enteric Coated Taj Pharma

  1. NAME OF THE MEDICINAL PRODUCT

Aspirin Tablets 75mg Enteric Coated Taj Pharma
Aspirin Tablets 150mg Enteric Coated Taj Pharma

  1. QUALITATIVE AND QUANTITATIVE COMPOSITION

a) Each enteric-coated tablet contains:
Aspirin BP?????????????????????????75mg
Excipients? ? ? ? ? ? ? ? ? ? ? ? ? ?q.s

b) Each enteric-coated tablet contains:
Aspirin BP?????????????? ????????150mg
Excipients? ? ? ? ? ? ? ? ? ? ? ? ? ?q.s

For the full list of excipients, see section 6.1.

  1. PHARMACEUTICAL FORM

Enteric-coated tablet.

  1. CLINICAL PARTICULARS

4.1 Therapeutic indications

– Secondary prevention of myocardial infarction.

– Prevention of cardiovascular morbidity in patients suffering from stable angina pectoris.

– History of unstable angina pectoris, except during the acute phase.

– Prevention of graft occlusion after Coronary Artery Bypass Grafting (CABG).

– Coronary angioplasty, except during the acute phase.

– Secondary prevention of transient ischaemic attacks (TIA) and ischaemic cerebrovascular accidents (CVA), provided intracerebral haemorrhages have been ruled out.

– Acute Myocardial infarction

4.2 Posology and method of administration

Adults

Secondary prevention of myocardial infarction:

The recommended dose is 75-160 mg once daily.

Prevention of cardiovascular morbidity in patients suffering from stable angina pectoris:

The recommended dose is 75-160 mg once daily.

History of unstable angina pectoris, except during the acute phase:

The recommended dose is 75-160 mg once daily.

Prevention of graft occlusion after Coronary Artery Bypass Grafting (CABG):

The recommended dose is 75-160 mg once daily.

Coronary angioplasty, except during the acute phase:

The recommended dose is 75-160 mg once daily.

Secondary prevention of transient ischaemic attacks (TIA) and ischaemic cerebrovascular accidents (CVA), provided intracerebral haemorrhages have been ruled out:

The recommended dose is 75-325 mg once daily.

Acute myocardial infarction

The recommended loading dose is 150-450 mg. The loading dose is administered as soon as possible after the onset of symptoms.

Elderly

In general, acetylsalicylic acids should be used with caution in elderly patients who are more prone to adverse events. The usual adult dose is recommended in the absence of severe renal or hepatic insufficiency (see sections 4.3 and 4.4). Treatment should be reviewed at regular intervals.

Paediatric population

Acetylsalicylic acid should not be administered to children and adolescents younger than 16 years, except on medical advice where the benefit outweighs the risk (see section 4.4).

Method of administration

For oral use.

4.3 Contraindications

– Hypersensitivity to salicylic acid compounds or prostaglandin synthetase inhibitors (e.g. certain asthma patients who may suffer an attack or faint) or to any of the excipients listed in section 6.1;

– Active, or history of recurrent peptic ulcer and/or gastric/intestinal haemorrhage, or other kinds of bleeding such as cerebrovascular haemorrhages;

– Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia;

– Severe hepatic impairment;

– Severe renal impairment;

– Gout;

– Doses >100 mg/day during the third trimester of pregnancy (see section 4.6);

– Methotrexate used at doses >15mg/week (see section 4.5).

4.4 Special warnings and precautions for use

Aspirin Tablets is not suitable for use as an anti-inflammatory/analgesic/antipyretic.

Recommended for use in adults and adolescents from 16 years of age. This medicinal product is not recommended for use in adolescents/children under 16 years unless the expected benefits outweigh the risks. Acetylsalicylic acid may be a contributory factor in the causation of Reye’s Syndrome in some children.

There is an increased risk of haemorrhage particularly during or after operative procedures (even in cases of minor procedures, e.g. tooth extraction). Use with caution before surgery, including tooth extraction. Temporary discontinuation of treatment may be necessary.

Aspirin Tablets is not recommended during menorrhagia where it may increase menstrual bleeding.

Aspirin Tablets is to be used with caution in cases of hypertension and when patients have a past history of gastric or duodenal ulcer or haemorrhagic episodes or are undergoing therapy with anticoagulants.

Patients should report any unusual bleeding symptoms to their physician. If gastrointestinal bleeding or ulceration occurs the treatment should be withdrawn.

Acetylsalicylic acid should be used with caution in patients with moderately impaired renal or hepatic function (contraindicated if severe), or in patients who are dehydrated since the use of NSAIDs may result in deterioration of renal function. Liver function tests should be performed regularly in patients presenting slight or moderate hepatic insufficiency.

Acetylsalicylic acid may promote bronchospasm and asthma attacks or other hypersensitivity reactions. Risk factors are existing asthma, hay fever, nasal polyps or chronic respiratory diseases. The same applies for patients who also show allergic reaction to other substances (e.g. with skin reactions, itching or urticaria).

Serious skin reactions, including Steven-Johnsons syndrome, have rarely been reported in association with the use of acetylsalicylic acid (see section 4.8). Aspirin Tablets should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Elderly patients are particularly susceptible to the adverse effects of NSAIDs, including acetylsalicylic acid especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2). Where prolonged therapy is required, patients should be reviewed regularly.

Concomitant treatment with Aspirin Tablets and other drugs that alter haemostasis (i.e. anticoagulants such as warfarin, thrombolytic and antiplatelet agents, anti-inflammatory drugs and selective serotonin reuptake inhibitors) is not recommended unless strictly indicated, because they may enhance the risk of haemorrhage (see section 4.5). If the combination cannot be avoided, close observation for signs of bleeding is recommended.

Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration, such as oral corticosteroids, selective serotonin-reuptake inhibitors and deferasirox (see section 4.5).

Acetylsalicylic acid should be avoided in late pregnancy and generally during breastfeeding (see section 4.6).

Acetylsalicylic acid in low doses reduces uric acid excretion. Due to this fact, patients who tend to have reduced uric acid excretion may experience gout attacks (see section 4.5).

The risk of hypoglycaemic effect with sulfonylureas and insulins may be potentiated with Aspirin Tablets taken at overdosage (see section 4.5).

4.5 Interaction with other medicinal products and other forms of interaction

Contraindicated combinations

Methotrexate (used at doses >15 mg/week):

The combined drugs, methotrexate and acetylsalicylic acid, enhance haematological toxicity of methotrexate due to the decreased renal clearance of methotrexate by acetylsalicylic acid. Therefore, the concomitant use of methotrexate (at doses >15 mg/week) with Aspirin Tablets is contraindicated (see section 4.3).

Not recommended combinations

Uricosuric agents, e.g. probenecid

Salicylates reverse the effect of probenecid. The combination should be avoided.

Combinations requiring precautions for use or to be taken into account

Anticoagulants e.g. coumarin, heparin, warfarin

Increased risk of bleeding due to inhibited thrombocyte function, injury of the duodenal mucosa and displacement of oral anticoagulants from their plasma protein binding sites. The bleeding time should be monitored (see section 4.4).

Anti-platelet agents (e.gclopidogrel and dipyridamole) and selective serotonin reuptake inhibitors (SSRIs; such as sertraline or paroxetine)

Increased risk of gastrointestinal bleeding (see section 4.4).

Antidiabetics, e.g. sulfonylureas

Salicylic may increase the hypoglycaemic effect of sulfonylureas.

Digoxin and lithium

Acetylsalicylic acid impairs the renal excretion of digoxin and lithium, resulting in increased plasma concentrations. Monitoring of plasma concentrations of digoxin and lithium is recommended when initiating and terminating treatment with acetylsalicylic acid. Dose adjustment may be necessary

Diuretics and antihypertensives

NSAIDs may decrease the antihypertensive effects of diuretics and other antihypertensive agents. As for other NSAIDs concomitant administration with ACE-inhibitors increases the risk of acute renal insufficiency.

Diuretics: Risk of acute renal failure due to the decreased glomerular filtration via decreased renal prostaglandin synthesis. Hydrating the patient and monitoring renal function at the start of the treatment is recommended.

Carbonic anhydrase inhibitors (acetazolamide)

May result in severe acidosis and increased central nervous system toxicity

Systemic corticosteroids

The risk of gastrointestinal ulceration and bleeding may be increased when acetylsalicylic acid and corticosteroids are co-administered (see section 4.4).

Methotrexate (used at doses <15 mg/week):

The combined drugs, methotrexate and acetylsalicylic acid, may increase haematological toxicity of methotrexate due to decreased renal clearance of methotrexate by acetylsalicylic acid. Weekly blood count checks should be done during the first weeks of the combination. Enhanced monitoring should take place in the presence of even mildly impaired renal function, as well, as in elderly.

Other NSAIDs

Increased risk of ulcerations and gastrointestinal bleeding due to synergistic effects.

Ibuprofen

Experimental data suggest that ibuprofen may inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 5.1).

Ciclosporin, tacrolimus

Concomitant use of NSAIDs and cyclosporin or tacrolimus may increase the nephrotoxic effect of ciclosporin and tacrolimus. The renal function should be monitored in case of concomitant use of these agents and acetylsalicylic acid.

Antacids

The excretion of acetylsalicylic acid is increased by alkaline urine, which can occur with some antacids.

Alcohol

Concomitant administration of alcohol and acetylsalicylic acid increases the risk of gastrointestinal bleeding.

4.6 Fertility, pregnancy and lactation

Pregnancy

Low doses (up to 100 mg/day):

Clinical studies indicate that doses up to 100 mg/day for restricted obstetrical use, which require specialised monitoring, appear safe.

Doses of 100- 500 mg/day:

There is insufficient clinical experience regarding the use of doses above 100 mg/day up to 500 mg/day. Therefore, the recommendations below for doses of 500 mg/day and above apply also for this dose range.

Doses of 500 mg/day and above:

Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre-and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of pregnancy, acetylsalicylic acid should not be given unless clearly necessary. If acetylsalicylic acid is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose

the foetus to:

– cardiopulmonary toxicity (with premature closure of the ductusarteriosus and pulmonary hypertension);

– renal dysfunction, which may progress to renal failure with oligo- hydramnios;

the mother and the neonate, at the end of pregnancy, to:

– possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.

– inhibition of uterine contractions resulting in delayed or prolonged labour.

Consequently, acetylsalicylic acid at doses of 100 mg/day and higher is contraindicated during the third trimester of pregnancy.

Breastfeeding

Low quantities of salicylates and of their metabolites are excreted into the breast milk. Since adverse effects for the infant have not been reported up to now, short-term use of the recommended dose does not require suspending lactation. In cases of long-term use and/or administration of higher doses, breastfeeding should be discontinued.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed with Aspirin 75mg/100mg/150mg Tablets.

Based on the pharmacodynamic properties and the side effects of acetylsalicylic acid, no influence on the reactivity and the ability to drive or use machines is expected.

4.8 Undesirable effects

Side effects are grouped on the basis of System Organ Class. Within each system organ class the frequencies are defined as: very common (?1/10), common (?1/100 to <1/10), uncommon (?1/1,000 to <1/100), rare (?1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data)

Blood and lymphatic system disorders Common:

Increased bleeding tendencies.

Rare:

Thrombocytopenia, granulocytosis, aplastic anaemia.

Not known:

Cases of bleeding with prolonged bleeding time such as epistaxis, gingival bleeding. Symptoms may persist for a period of 4?8 days after acetylsalicylic acid discontinuation. As a result there may be an increased risk of bleeding during surgical procedures.

Existing (haematemesis, melaena) or occult gastrointestinal bleeding, which may lead to iron deficiency anaemia (more common at higher doses).

Immune system disorders Rare:

Hypersensitivity reactions, angio-oedema, allergic oedema, anaphylactic reactions including shock.

Metabolism and digestive system disorders Not known:

Hyperuricemia.

Nervous system disorders Rare:

Intracranial haemorrhage.

Not known:

Headache, vertigo.

Ear and labyrinth disorders Not known:

Reduced hearing ability; tinnitus.

Vascular disorders Rare:

Hemorrhagic vasculitis.

Respiratory, thoracic and mediastinal disorders Uncommon:

Rhinitis, dyspnoea.

Rare:

Bronchospasm, asthma attacks.

Reproductive system and mammary disorders Rare:?Menorrhagia.
Gastrointestinal disorders Common:

Dyspepsia.

Rare:

Severe gastrointestinal haemorrhage, nausea, vomiting.

Not known:

Gastric or duodenal ulcers and perforation.

Hepatobiliary disorders Not known:

Hepatic insufficiency.

Skin and subcutaneous tissue disorders Uncommon:

Urticaria.

Rare:

Steven-Johnsons syndrome, Lyell’s syndrome, purpura, erythema nodosum, erythema multiforme.

Renal and urinary tract disorders Not known:?Impaired renal function, salt and water retention.

?

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important.

4.9 Overdose

Although considerable inter-individual variations are involved, it can be considered that the toxic dose is about 200 mg/kg in adults and 100 mg/kg in children. The lethal dose of acetylsalicylic acid is 25-30 grams. Plasma salicylate concentrations above 300 mg/l indicate intoxication. Plasma concentrations above 500 mg/l in adults and 300 mg/l in children generally cause severe toxicity.

Overdose may be harmful for elderly patients and particularly for small children (therapeutic overdose or frequent accidental intoxications may be fatal).

Symptoms of moderate intoxications

Tinnitus, hearing disorders, headache, vertigo, confusion and gastrointestinal symptoms (nausea, vomiting and abdominal pain).

Symptoms of severe intoxications

Symptoms are related to severe disruption of the acid-base balance. In the first instance, hyperventilation occurs, which results in respiratory alkalosis. Respiratory acidosis ensues due to suppression of the respiratory centre. In addition, metabolic acidosis occurs as a result of the presence of salicylate.

Since younger children are often not seen until they have reached a late stage of intoxication, they are usually in the stage of acidosis.

Furthermore, the following symptoms may occur: hyperthermia and perspiration, resulting in dehydration: feelings of restlessness, convulsions, hallucinations and hypoglycaemia. Depression of the nervous system may lead to coma, cardiovascular collapse or respiratory arrest.

Treatment of overdose

If a toxic dose has been ingested, hospital admission is required. In the event of moderate intoxication, inducing the patient to vomit should be attempted.

If this fails, gastric lavage may be attempted during the first hour after ingestion of a substantial amount of the medicine. Afterwards, administer activated carbon (adsorbent) and sodium sulfate (laxative).

Activated charcoal may be given as a single dose (50 g for an adult, 1 g/kg body weight for a child up to 12 years).

Alkalisation of the urine (250 mmol NaHCO3, for three hours) whilst checking urine pH levels. In the event of severe intoxication, haemodialysis is to be preferred. Other symptoms to be treated symptomatically.

  1. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antithrombotic agents: platelet aggregation inhibitors excl. heparin,

Acetylsalicylic acid inhibits the platelet activation: blocking the platelet cyclooxygenase by acetylation, it inhibits thromboxane A2 synthesis, a physiological activating substance released by the platelets and which would play a role in the complications of the atheromatosic lesions.

Inhibition of TXA2-synthesis is irreversible, because thrombocytes, which have no nucleus, are not capable (due to lack of protein synthesis capability) to synthesise new cyclooxygenase, which had been acetylated by acetylsalicylic acid.

The repeated doses from 20 to 325 mg involve an inhibition of the enzymatic activity from 30 to 95%.

Due to the irreversible nature of the binding, the effect persists for the lifespan of a thrombocyte (7-10 days). The inhibiting effect does not exhaust during prolonged treatments and the enzymatic activity gradually begins again upon renewal of the platelets 24 to 48 hours after treatment interruption.

Acetylsalicylic acid extends bleeding time on average by approximately 50 to 100%, but individual variations can be observed.

Experimental data suggest that ibuprofen may inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly.

In one study, when a single dose of ibuprofen 400 mg was taken within 8 h before or within 30 min after immediate release acetylsalicylic acid dosing (81 mg), a decreased effect of acetylsalicylic acid on the formation of thromboxane or platelet aggregation occurred. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use.

5.2 Pharmacokinetic properties

Absorption

After oral administration, acetylsalicylic acid is rapidly absorbed from the gastrointestinal tract. However, a significant portion of the dosage is already hydrolysed to salicylic acid in the intestinal wall during the absorption process.

Distribution

Acetylsalicylic acid as well as the main metabolite salicylic acid, are extensively bound to plasma proteins, primarily albumin, and distributed rapidly into all parts of the body. Maximum plasma concentration is reached after 0.3 – 2 hours (total salicylate). The volume of distribution of acetylsalicylic acid is ca. 0.16 l/kg of body weight.

Biotransformation

Acetylsalicylic acid is rapidly metabolised to salicylic acid, with a half-life of 15-30 minutes. Salicylic acid is subsequently predominantly converted into glycine and glucuronic acid conjugates.

Elimination kinetics of salicylic acid is dose-dependent, because the metabolism is limited by liver enzyme capacity. Thus, elimination half-time varies and is 2-3 hours after low doses (75 mg ? 160 mg).

Excretion

Salicylic acid and its metabolites are predominantly excreted via the kidneys.

5.3 Preclinical safety data

The nonclinical safety profile of acetylsalicylic acid is well documented.

In experimental animal studies, salicylates have shown no other organ injury than renal damage. In rat studies, fetotoxicity and teratogenic effects were observed with acetylsalicylic acid at maternotoxic doses. Clinical relevance is unknown as the doses used in non-clinical studies are much higher (7 times at least) than the maximal recommended doses in targeted cardiovascular indications. Acetylsalicylic acid was extensively investigated with regard to mutagenic and carcinogenic effects. The results as a whole show no relevant signs for any mutagenic or carcinogenic effects in mice and rat studies.

  1. PHARMACEUTICAL PARTICULARS
  2. a) Each enteric coated tablet contains:

Aspirin BP??????????????????????????????????????? 75mg

Excipients???????????????????????????????????????????? q.s.

  1. b) Each enteric coated tablet contains:

Aspirin BP?????????????????????????????????????? 150mg

Excipients????????????????????????????????????????????? q.s.

6.1 List of excipients

Microcrystalline cellulose

Maize starch

Silica, colloidal anhydrous

Stearic acid

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Do not store above 25?C.

6.5 Nature and contents of container

PVC/PVDC/Al blisters.

Pack sizes: Blisters: 7, 14, 28, 30, 50, 90, 100 and 500mg modified-release tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. MANUFACTURED IN INDIA BY:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of ?Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail:?tajgroup@tajpharma.com

PACKAGE LEAFLET: INFORMATION FOR THE USER

ASPIRIN TABLETS 75MG / 150MG ENTERIC COATED TAJ PHARMA

Aspirin Tablets

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same asyours.
  • If you get any side effects, talk to your doctor, or pharmacist. This includes any possible side effects not listed in this leaflet. See section4.

WHAT IS IN THIS LEAFLET:

  1. What Aspirin is and what it is used for
  2. What you need to know before you take aspirin
  3. How to take aspirin
  4. Possible side effects
  5. How to storeAspirin
  6. Contents of the pack and other information

 

1.??? WHAT ASPIRIN IS AND WHAT IT IS USED FOR

Aspirin contains acetylsalicylic acid, which in low doses belong to a group of medicines called antiplatelet agents. Platelets are tiny cells in the blood that cause the blood to clot and are involved in thrombosis. When a blood clot occurs in an artery it stops the blood flowing and cuts off the oxygen supply. When this happens in the heart it can cause a heart attack or angina; in the brain it can cause a stroke. Aspirin is taken to reduce the risk of blood clots forming and thereby prevent further:

  • heart attacks
  • strokes
  • Cardiovascular problems in patients who suffer from stable or unstable angina (a type of chest pain).

Aspirin is also used to prevent the formation of blood clots after certain types of heart surgery in order to widen or to unblock the blood vessels.
Aspirin is also used for the treatment of acute myocardial infarction.

  1. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ASPIRIN

Do not take Aspirin

  • if you are allergic to acetylsalicylic acid or any of the ingredients in Aspirin (listed in section6)
  • are allergic to other salicylates or non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are often used for arthritis or rheumatism and pain.
  • If you have had an asthma attack or swelling of some parts of the body e.g. face, lips, throat or tongue (angioedema) after taking salicylates or NSAIDs.
  • If you currently have or have ever had an ulcer in your stomach or small intestine or any other type of bleeding like a stroke.
  • If you have ever had the problem of your blood not clotting properly.
  • have severe liver or kidney problems
  • if you have severe heart problems which can cuase shortness of breath and ankle swelling
  • If you are in your last 3 months of pregnancy; you must not use higher doses than 100 mg per day (see section ?Pregnancy and breast-feeding?).
  • If you are taking a medicine called methotrexate (e.g. for cancer or rheumatoid arthritis) in doses higher than 15 mg per week.

Warnings and precautions

Talk to your doctor before taking Aspirin:

  • If you have trouble with your kidneys, liver or heart.
  • If you have or have ever had problems with your stomach or small intestine.
  • If you have uncontrolled high blood pressure.
  • If you are asthmatic, have hay fever, nasal polyps or other chronic respiratory diseases; acetylsalicylic acid may induce an asthma attack.
  • if you have ever had gout.
  • if you have heavy menstrual periods.
  • If you suffer from a deficiency of the enzyme glucose-6-phosphate dehydrogenase(G6PD)

You must immediately seek medical advice, if your symptoms get worse or if you experience severe or unexpected side effects e.g. unusual bleeding symptoms, serious skin reactions or any other sign of serious allergy (see section ?Possible side effects?).

Inform your doctor if you are planning to have an operation (even a minor one, such as tooth extraction) since acetylsalicylic acid is blood-thinning there may be an increased risk of bleeding.

You should take care not to become dehydrated (you may feel thirsty with a dry mouth) since the use of acetylsalicylic acid at the same time may result in deterioration of kidney function.

This medicinal product is not suitable as a pain killer or fever reducer.

If any of the above applies to you, or if you are not sure, speak to your doctor or pharmacist.

Children and adolescents

Acetylsalicylic acid may cause Reye?s syndrome when given to children. Reye?s

syndrome is a very rare disease which affects the brain and liver and can be live threatening. For this reason, Aspirin should not be given to children aged under 16 years, unless on the advice of a doctor.

Other medicines and Aspirin

Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.

The effect of treatment may be influenced if acetylsalicylic acid is taken at the same time as some other medicines for:

  • thinning of the blood/prevention of clots (e.g. warfarin, heparin, clopidogrel, alteplase)
  • rejection of organ after transplantation (cyclosporine, tacrolimus)
  • high blood pressure (e.g. diuretics and ACE-inhibitors)
  • regulation of the heartbeat(digoxin)
  • manic-depressive illness(lithium)
  • pain and inflammation (e.g. NSAIDs such as ibuprofen, or steroids)
  • gout (e.g. probenecid)
  • epilepsy (valproate, phenytoin)
  • glaucoma(acetazolamide)
  • cancer or rheumatoid arthritis (methotrexate; in doses lower than 15 mg per week)
  • diabetes (e.g. glibenclamide,insulin)
  • depression (selective serotonin reuptake inhibitors (SSRIs) such as sertraline or paroxetine).
  • use as hormone replacement therapy when the adrenal glands or pituitary gland have been destroyed or removed, or to treat inflammation, including rheumatic diseases and inflammation of the intestines (corticosteroids)

Aspirin with food, drink and alcohol

Drinking alcohol may possibly increase the risk of gastrointestinal bleeding and prolong bleeding time.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Pregnant women should not take acetylsalicylic acid during pregnancy unless advised by their doctor.

You should not take Aspirin if you are in the last 3 months of pregnancy, unless you are advised to do so by your doctor and then the daily dose should not exceed 100 mg (see section ?Do not take Aspirin?). Regular or high doses of this medicinal product during late pregnancy can cause serious complications in the mother or baby.

Breast-feeding women should not take acetylsalicylic acid unless advised by their doctor.

Driving and using machines

Aspirin should not affect your ability to driveand use machines.?

Aspirin contains lactose

If you have been told that you have an intolerance to certain sugars, please inform your doctor before taking this medicine.

  1. HOW TO TAKEASPIRIN

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Adults

Prevention of heart attacks:

  • The recommended dose is 75-160 mg oncedaily.
  • Prevention of strokes:
  • The recommended dose is 75-300 mg oncedaily.
  • Prevention of cardiovascular problems in patients who suffer from stable or unstable angina (a type of chest pain):
  • The recommended dose is 75-160 mg oncedaily.
  • Prevention formation of blood clots after certain types of heart surgery:
  • The recommended dose is 75-160 mg oncedaily.
  • Treatment of acute myocardial infarction:
  • The recommended initial dose is 150-500 mg followed by a lower dose (75-160 mg)thereafter.

This medicine should not be used at higher doses unless advised by a doctor, and then the dose should not exceed 300 mg a day.

Older people

As for adults. In general, acetylsalicylic acids should be used with caution in elderly patients who are more prone to adverse events. Treatment should be reviewed at regular intervals.

Children and adolescents

Acetylsalicylic acid should not be administered to children and adolescents younger than 16 years, unless prescribed by a doctor (see section ?Warnings and precautions?).

Method of administration Fororal use.
The tablets should be swallowed with sufficient fluid (1/2 glass of water)

If you take more Aspirin than you should

If you (or someone else) accidentally take too many tablets, you should tell your doctor at once or contact immediately the nearest casualty department. Show any leftover medicines or the empty packet to the doctor.

Symptoms of overdose may include ringing in ears, hearing problems, headache, dizziness, confusion, nausea, vomiting and abdominal pain. A large overdose can lead to more rapid breathing than normal

(hyperventilation), fever, excess sweating, restlessness, seizures, hallucinations, low blood sugar, coma and shock.

If you forget to take Aspirin

If you miss a dose, wait until it is time for your next dose, then go on as normal. Do not take a double dose to make up for a forgotten tablet.

If you stop taking Aspirin

Do not stop taking Aspirin without asking your doctor.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you notice any of the following serious side effects, stop taking Aspirin and contact a doctor immediately:
  • Sudden wheezing, swelling of your lips, face or body, rash, fainting or difficulties swallowing (severe allergic reaction).
  • Reddening of the skin with blisters or peeling and may be associated with a high fever and joint pains.
  • This could be erythema multiforme, Stevens-Johnson syndrome or Lyell?s syndrome.
  • Unusual bleeding, such as coughing up blood, blood in your vomit or urine, or black stools.

Other side effects include:

Common side effects (may affect up to 1 in 10 people)

  • Nausea, vomiting, diarrhoea
  • Increased tendency for bleeding.

Rare side effects (may affect up to 1 in 1,000 people)

  • Severe bleeding in the stomach or intestines, brain haemorrhage; the altered number of blood cells.
  • Cramps in the lower respiratory tract, asthma attack.
  • Inflammation in the blood vessels.
  • Bruising with purple spots (cutaneous bleeding).
  • Severe skin reactions such as rash known as erythema multiforme and it?s life-threatening forms Stevens-Johnson syndrome and Lyell?ssyndrome.
  • Hypersensitivity reactions, such as swelling of e.g. lips, face or body, or shock.
  • Reye?s syndrome (a very rare disease in children which affects the brain and liver (see section 2 ?Children and adolescents?.)

Abnormal heavy or prolonged menstrual periods

Side effects with frequency not known (frequency cannot be estimated from the available data)

  • Ringing in your ears (tinnitus) or reduced hearing ability.
  • Ulcers in stomach or small intestine and perforation.
  • Prolonged bleeding time.
  • Impaired kidney function, acute renal failure.
  • Impaired liver function, increased liver enzymes.
  • High level of uric acid or low levels of sugar in the blood.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

5. HOW TO STORE ASPIRIN

Keep this medicine out of the sight and reach of children. Do not store above 30?C.

Keep the blister in the outer carton in order to protect from moisture.

Do not use Aspirin after the expiry date which is stated on the carton or blister after EXP. The expiry date refers to the last day of that month.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. CONTENTS OF THE PACK AND OTHER INFORMATION WHAT ASPIRIN CONTAINS

a) Each enteric-coated tablet contains:
Aspirin BP?????????????????????????75mg
Excipients? ? ? ? ? ? ? ? ? ? ? ? ?q.s

b) Each enteric-coated tablet contains:
Aspirin BP?????????????? ????????150mg
Excipients????????????????????????q.s

Pack sizes: Blisters: 7, 14, 28, 30, 50, 90, 100 and 500mg modified-release tablets.

Not all pack sizes may be marketed.

7. MANUFACTURED IN INDIA BY:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of ?Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail:?tajgroup@tajpharma.com

Leave a Reply

What people say about our doctor?

Loading…

More from Portfolio

Loading…
  • Fluoxetine Capsules USP 40mg Taj Pharma

    Name of the Medicinal Product Fluoxetine Capsules USP 10mg Taj Pharma Fluoxetine Capsules USP 20mg Taj Pharma Fluoxetine Capsules USP 40mg Taj Pharma Qualitative and Quantitative Composition a) Each Hard Gelatin Capsule Contains: Fluoxetine Hydrochloride USP Equivalent to Fluoxetine? ? ? ? 10mg Excipients? ? ? ? ? ? ? ? ? ? ? ? […]

  • Amlodipine Besylate Tablets USP 2.5mg Taj Pharma

    Name of the medicinal product Amlodipine Besylate Tablets USP 2.5mg Taj Pharma Amlodipine Besylate Tablets USP 5mg Taj Pharma Amlodipine Besylate Tablets USP 10mg Taj Pharma Qualitative and quantitative composition a) Each Tablet Contains: Amlodipine Besylate USP Equivalent to Amlodipine? ? ?2.5mg Excipients? ? ? ? ? ? ? ? ? ? ? ? ? […]

  • Fenofibrate Capsules 160mg Taj Pharma

    Name of the medicinal product Fenofibrate Capsules 160mg Taj Pharma Fenofibrate Capsules 200mg Taj Pharma Qualitative and quantitative composition a) Each hard gelatin capsule contains: Fenofibrate (Micronized)? ? ? ? ? ? ?160mg Excipients? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? q.s Colour: Approved […]

  • Fluconazole Tablets USP 200mg Taj Pharma

    NAME OF THE MEDICINAL PRODUCT Fluconazole Tablets USP 50mg Taj Pharma Fluconazole Tablets USP 100mg Taj Pharma Fluconazole Tablets USP 150mg Taj Pharma Fluconazole Tablets USP 200mg Taj Pharma QUALITATIVE AND QUANTITATIVE COMPOSITION a) Each tablet contains: Fluconazole USP? ? ? ? ? ? ? ? ? 50mg Excipients? ? ? ? ? ? ? […]